WFRF:(Wang Yang Yang)
Search: WFRF:(Wang Yang Yang) > (2005-2009) > Potential effects o...
- 21 of 154
- Previous record
- Next record
- To hitlist
Potential effects of peroxisome proliferator-activated receptor activator on LPS-induced lung injury in rats
- Wang, Xiangdong (author)
- Wang, Yaoli (author)
-
- Zhao, Xia (author)
- Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine
- show more...
- Song, Zhenju (author)
- Yang, Dong (author)
- Bai, Chunxue (author)
- show less...
- (creator_code:org_t)
- Elsevier BV, 2009
- 2009
- English.
- In: Pulmonary Pharmacology & Therapeutics. - : Elsevier BV. - 1522-9629 .- 1094-5539. ; 22:4, s. 318-325
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Multiple factors contribute to the pathogenesis and prognosis of chronic obstructive pulmonary disease (COPD), still requiring new therapeutic strategies and medications for the disease. The aim of the present study is to investigate the model of lipopolysaccharide (LPS)-induced chronic lung injury and hyperinflation and test therapeutic effects of peroxisome proliferator-activated receptor (PPAR)-gamma agonist. Wister rats were challenged with intra-tracheal instillation of LPS at concentrations of 0.006, 0.060, 0.600, and 6.000 mg/ml per kg, twice a week, for 1, 2, 4 and 6 weeks. PPAR activator, 15-deoxy-Delta(12,14)-prostaglandin J2 (15D-PGJ2), or vehicle (PBS) was administered orally and daily at the dose of 1 and 10 mg/ml per kg in animals challenged with LPS or PBS at the dose of 0.060 mg/ml per kg body weight twice a week for 4 weeks. We found that intra-tracheal exposure of LPS resulted in a dose-dependent pattern of chronic lung hyperinflation and hypertrophy, increased alveolar enlargement, reduced vascular endothelial growth factor (VEGF) and elevated tissue inhibitor of metalloproteinases (TIMP)-1 levels in bronchoalveolar lavage (BAL) fluid, and early changes of leukocyte influx and interferon (IFN)-gamma levels in bronchoalveolar lavage (BAL) fluid. PPAR-gamma agonist ameliorated these changes related with the dose used. LPS-induced lung disease model shows some similarities with human disease, and PPAR-gamma agonist may be an alternative for COPD therapy. (C) 2009 Elsevier Ltd. All rights reserved.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
Keyword
- Emphysema
- PPAR-gamma
- TIMP-1
- VEGF
- Hyperinflation
- LPS
- COPD
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
- Pulmonary Pharmacology & Therapeutics (Search for host publication in LIBRIS)
To the university's database
- 21 of 154
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Wang, Xiangdong
- Wang, Yaoli
- Zhao, Xia
- Andersson, Rolan ...
- Song, Zhenju
- Yang, Dong
- show more...
- Bai, Chunxue
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Surgery
- Articles in the publication
- Pulmonary Pharma ...
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
